Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call on March 19 at 8:30 a.m. Eastern Time
YAVNE, Israel , March 13, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the fourth
View HTML
Toggle Summary MediWound to Present at Two Investor Conferences
YAVNE, Israel , March 08, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will present a corporate overview at the Cowen &
View HTML
Toggle Summary MediWound Reports Third Quarter 2017 Financial Results
NexoBrid ® sales grow 74% year-to-date Raised gross proceeds of $25.2 million through public equity offering Awarded additional $32 million from BARDA to support NexoBrid R&D programs Conference call begins today at 8:30 a.m. Eastern Standard Time YAVNE, Israel , Nov.
View HTML
Toggle Summary Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares; MediWound Weighing an Appeal
YAVNE, Israel , Nov. 13, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Tel Aviv District Court ordered that MediWound (the
View HTML
Toggle Summary MediWound to Host Third Quarter 2017 Financial Results Conference Call on November 16, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel , Nov. 10, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the nine
View HTML
Toggle Summary MediWound Announces Exercise of Underwriters’ Option to Purchase Additional Shares
YAVNE, Israel , Oct. 27, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that the underwriters of its previously announced
View HTML
Toggle Summary MediWound Appoints Mr. Stephen T. Wills as Chairman to its Board of Directors
YAVNE, Israel , Oct. 25, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr. Stephen T.
View HTML
Toggle Summary MediWound Further Expands NexoBrid's® Global Outreach through New Distribution Agreement in Taiwan with Holy Stone Healthcare
YAVNE, Israel , Oct. 16, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company specializing in the development of innovative therapies to address unmet needs in severe burn and wound management, today announced an agreement with Holy Stone Healthcare,
View HTML
Toggle Summary MediWound Ltd. Announces Pricing of $22 Million Public Offering of Ordinary Shares
YAVNE, Israel , Sept. 19, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) today announced the pricing of an underwritten public offering of 4,400,000 of its ordinary shares at a price to the public of $5.00 per share. All of the ordinary shares are being offered by MediWound .
View HTML
Toggle Summary MediWound Ltd. Announces Public Offering of Ordinary Shares
YAVNE, Israel , Sept. 18, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, today announced that it has commenced an underwritten public offering of its
View HTML